

DATE:	2022 April 18
TO:	Lab Directors and Physicians
FROM:	Alberta Precision Laboratories (APL) – Public Health Laboratory
RE:	<b>Serology Platform Change</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Effective April 18, 2022, the majority of serology testing for several infectious disease markers will be performed on the Abbott Alinity *i* platform for patients across Alberta.
- There are no changes to the types of blood collection tubes used, or the volume requirements.
- There are no changes to the process for sample submission, or the reporting of results.

### Background

- The APL—Public Health Laboratory performs serology testing for markers of several infectious diseases. Many of these tests are performed using Abbott Architect instruments, which will be replaced with the Abbott Alinity *i* platform. Therefore, the following tests will transition to equivalent tests on Alinity instruments:
  - **CMV** IgG antibody, including IgG avidity,
  - **EBV** VCA IgM, VCA IgG, and EBNA-1 IgG,
  - **HAV** antibodies (IgM and IgG),
  - **HBV** surface antigen (qualitative and quantitative), surface antibody, e antigen, e antibody, and core antibody (total and IgM),
  - **HCV** antibody,
  - **HIV** antigen/antibody combo (screen),
  - **HTLV-I/II** antibody,
  - **Rubella** IgG,
  - **SARS-CoV-2** nucleocapsid IgG and spike RBD IgG,
  - **Toxoplasma** IgM and IgG, and
  - **Syphilis** screen (*Treponema pallidum* antibody).
- These Alinity tests are all Health Canada-approved for clinical use and their performance has been evaluated by APL - Public Health Laboratory. This change will not affect test availability or turn-around time. This will not affect nucleic acid tests or any serology tests using other platforms (e.g., CMV total antibody).

### Actions Required

- No actions are required.

### Inquiries and feedback may be directed to

- Dr. Natalie Marshall, Clinical Microbiologist, APL—Public Health Laboratory, [natalie.marshall@aplabs.ca](mailto:natalie.marshall@aplabs.ca)

### Approved by

- Dr. Graham Tipples, Medical/Scientific Director, APL—Public Health Laboratory